Five-year follow-up of patients with advanced chronic lymphocytic leukemia treated with allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning
about
Stem cell transplantation in chronic lymphocytic leukemiaCARs in chronic lymphocytic leukemia -- ready to driveClinical implications of the molecular genetics of chronic lymphocytic leukemiaHematopoietic stem cell allografting for chronic lymphocytic leukemia: a focus on reduced-intensity conditioning regimensThe biology and clinical significance of acquired genomic copy number aberrations and recurrent gene mutations in chronic lymphocytic leukemiaSequential ofatumumab and lenalidomide for the treatment of relapsed and refractory chronic lymphocytic leukemia and small lymphocytic lymphoma.Long-term outcomes of patients with persistent indolent B cell malignancies undergoing nonmyeloablative allogeneic transplantation.Chronic lymphocytic leukemia in young (≤ 55 years) patients: a comprehensive analysis of prognostic factors and outcomesAllogeneic hematopoietic cell transplantation after conditioning with 131I-anti-CD45 antibody plus fludarabine and low-dose total body irradiation for elderly patients with advanced acute myeloid leukemia or high-risk myelodysplastic syndrome.A modified EBMT risk score and the hematopoietic cell transplantation-specific comorbidity index for pre-transplant risk assessment in adult acute lymphoblastic leukemia.Pretransplant comorbidities predict severity of acute graft-versus-host disease and subsequent mortality.NCI First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: report from the Committee on the Epidemiology and Natural History of Relapse following Allogeneic Cell TrAllogeneic hematopoietic cell transplantation: the state of the artNCI First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: Report from the Committee on Treatment of Relapse after Allogeneic Hematopoietic Stem Cell TransplantatioOutcomes of human leukocyte antigen-matched sibling donor hematopoietic cell transplantation in chronic lymphocytic leukemia: myeloablative versus reduced-intensity conditioning regimens.Comorbidity-age index: a clinical measure of biologic age before allogeneic hematopoietic cell transplantation.Role of allogeneic transplantation in patients with chronic lymphocytic leukemia in the era of novel therapies: a reviewThe B-cell tumor-associated antigen ROR1 can be targeted with T cells modified to express a ROR1-specific chimeric antigen receptor.Allogeneic hematopoietic cell transplantation in the treatment of chronic lymphocytic leukemia: why and when?Allogeneic transplantation for chronic lymphocytic leukemiaTransplantation in chronic lymphocytic leukemia: does it still matter in the era of novel targeted therapies?BFR (bendamustine, fludarabine, and rituximab) allogeneic conditioning for chronic lymphocytic leukemia/lymphoma: reduced myelosuppression and GVHDManaging high-risk CLL during transition to a new treatment era: stem cell transplantation or novel agents?Relapse of lymphoma after allogeneic hematopoietic cell transplantation: management strategies and outcome.Nonmyeloablative allogeneic stem cell transplantation in relapsed/refractory chronic lymphocytic leukemia: long-term follow-up, prognostic factors, and effect of human leukocyte histocompatibility antigen subtype on outcome.Acquired genomic copy number aberrations and survival in chronic lymphocytic leukemia.Chronic lymphocytic leukemia: treatment options for patients with refractory disease.Outcomes of Patients With Chronic Lymphocytic Leukemia and Richter's Transformation After Transplantation FailureAllogeneic hematopoietic cell transplantation in patients with myelodysplastic syndrome and concurrent lymphoid malignancy.Allogeneic stem cell transplant in patients with chronic lymphocytic leukemia with 17p deletion: consult-transplant versus consult- no-transplant analysis.State-of-the-Art Management of Patients Suffering from Chronic Lymphocytic Leukemia.Prospective Validation of the Predictive Power of the Hematopoietic Cell Transplantation Comorbidity Index: A Center for International Blood and Marrow Transplant Research StudyOutcomes after matched unrelated donor versus identical sibling hematopoietic cell transplantation in adults with acute myelogenous leukemia.Prophylactic rituximab after allogeneic transplantation decreases B-cell alloimmunity with low chronic GVHD incidenceReduced intensity allogeneic haematopoietic cell transplantation for chronic lymphocytic leukaemia: related donor and umbilical cord allografting.Induction of TAp73 by platinum-based compounds to overcome drug resistance in p53 dysfunctional chronic lymphocytic leukemiaA disease risk index for patients undergoing allogeneic stem cell transplantation.Long-term survival of patients with CLL after allogeneic transplantation: a report from the European Society for Blood and Marrow Transplantation.Allogeneic hematopoietic cell transplant with fludarabine-based reduced-intensity conditioning as treatment for advanced chronic lymphocytic leukemia.Phase I clinical trial of CpG oligonucleotide 7909 (PF-03512676) in patients with previously treated chronic lymphocytic leukemia
P2860
Q24642921-84C8A15B-E488-48EB-B475-3B6DB2041611Q26830526-70036D33-0CED-4513-9812-07690D152321Q26830955-F06C1841-32F3-4FDE-A385-BE4FC8C6AEDDQ27021206-2C83AB36-95A9-4AD1-BB05-0C5C7787B40AQ27024411-74A83052-6527-49FB-B6E1-96E5DEECE7BBQ33417117-99A6144A-0BBD-4B05-89D1-A56B75F22748Q33419003-D7E8FCDC-DCD3-4AAF-8769-8AC29BE0D570Q33558148-530C277C-4E9F-47AB-B83B-F3464D0477B8Q33560410-5F529658-67E8-4173-95C0-FF851EDEEC0AQ33829105-20B9A2C4-BD53-4A96-83DE-E218315B76ABQ33886907-46619690-90D3-4D86-A0B6-FF0A8C28C8E3Q34044024-92091A23-8F28-49E6-AFA2-9444F67E10A7Q34145155-FB47E540-6115-4755-9818-BE71EE56B5E4Q34202277-C639E048-9341-44AE-9DAE-A4D468F25158Q34240410-40842B54-B1AF-4CE1-84FE-5F2369CB101AQ34260505-A58742F5-541D-4A70-A949-7CC7404708E4Q34348572-A76DEDF9-FA45-48AD-8E7D-7E54F975B58DQ34374056-854A0C10-3625-4D22-8CDD-19680B845E46Q34549285-0F06DA12-F343-4EF0-B858-1E828599EFECQ34549313-FC7EEDC0-87FB-4600-ADB1-F47BC1CD4A76Q34625543-BA528F3D-00D4-49A4-8EAF-780DD240C311Q34660110-93EC8DD4-1BE8-439E-AC04-0FF305ACD419Q34769213-12E3F4E9-9880-4D23-8B98-3FBCE68BC79EQ35093521-7F042CA8-CE8E-4E0E-A5DF-A0B6BDA30CAFQ35211577-38199BE6-8159-4C04-9D12-ACD4F1FC1BA0Q35220403-A8AE7730-4FF7-4734-A80C-5711CDB53411Q35382716-EF750E74-1B48-4068-BF7D-966E0F3862F4Q35563832-5EEB9882-CE8F-438C-9E14-54AED1119AC2Q35613049-8AEF24E6-4013-436E-86D3-35D8908AF26BQ35679601-DE878CB7-90AB-4AFB-98DB-2BB1D4613848Q35860550-0EC78EED-50A7-4A53-A465-B054B9A46465Q35882830-EC4DC323-80AC-4D3E-BA2B-4FCD9E16B1DBQ35953348-8FE13598-D3B5-4705-A693-867B6953AA4AQ36057911-0D6898F6-F322-489A-89A6-DCD3630BA688Q36092009-8FF3C293-7637-4ADF-84C8-1FA97E1A10D6Q36118111-466CA4D4-3653-48BB-A462-1C8F9DBC85EFQ36141944-8D5E348F-8B49-44F5-B6A2-DEA08293B054Q36219840-59C9CAF1-957B-4928-B3D4-0A53A893AB59Q36222747-4F80FC91-12B3-4FA4-AE5F-0BD832A94874Q36222910-BF426AE7-4FBD-41FA-BE45-24EC5DFA7228
P2860
Five-year follow-up of patients with advanced chronic lymphocytic leukemia treated with allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 15 September 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Five-year follow-up of patient ...... nonmyeloablative conditioning
@en
Five-year follow-up of patient ...... nonmyeloablative conditioning.
@nl
type
label
Five-year follow-up of patient ...... nonmyeloablative conditioning
@en
Five-year follow-up of patient ...... nonmyeloablative conditioning.
@nl
prefLabel
Five-year follow-up of patient ...... nonmyeloablative conditioning
@en
Five-year follow-up of patient ...... nonmyeloablative conditioning.
@nl
P2093
P2860
P50
P356
P1476
Five-year follow-up of patient ...... nonmyeloablative conditioning
@en
P2093
Amelia Langston
Benedetto Bruno
Dietger Niederwieser
Edward Agura
James C Wade
Jerald Radich
Judith Shizuru
Karl G Blume
Michael A Pulsipher
Michael Maris
P2860
P304
P356
10.1200/JCO.2007.15.4757
P407
P577
2008-09-15T00:00:00Z